The CBX5 Knockout 769-P Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the 769-P human clear cell renal cell carcinoma line, designed for loss-of-function studies of the CBX5 gene. This product provides a heterogeneous pool of cells carrying targeted disruptions in CBX5, enabling the study of heterochromatin protein 1?? (HP1??) functions without clonal selection artifacts. The polyclonal format preserves genetic diversity while ensuring robust knockout efficiency across the population, making it suitable for pooled functional assays and high-throughput screening applications.
The parental 769-P cell line was established from a primary clear cell renal cell carcinoma and is widely employed as a model for kidney cancer research. These epithelial cells retain key characteristics of renal cell carcinoma, including VHL inactivation and dysregulated hypoxia signaling, providing a clinically relevant background for investigating epigenetic mechanisms in tumorigenesis. The 769-P line is adherent and exhibits stable growth properties, facilitating a range of cell-based assays.
CBX5, also known as HP1??, is a conserved chromatin protein that organizes heterochromatin and mediates transcriptional repression. Its chromodomain binds H3K9me3, a histone mark deposited by SUV39H1 and SUV39H2 methyltransferases. This nucleates repressive complexes, recruiting DNMT1, Lamin B receptor (LBR), TRIM28, and HP1BP3 to propagate silencing. CBX5 function is modulated by Aurora B phosphorylation and SUMOylation. Downstream, it silences repetitive elements and tumor suppressor loci, and regulates p21 expression, connecting heterochromatin maintenance to the p53 pathway.
Dysregulation of heterochromatin organization is a hallmark of cancer, and CBX5 has been proposed to contribute to the epigenetic silencing of tumor suppressor genes in renal cell carcinoma. In 769-P cells, disrupting CBX5 expression provides a unique tool to dissect how loss of HP1?? function impacts heterochromatin architecture, gene expression, and cancer cell phenotypes such as proliferation and colony formation. This model enables researchers to examine the interplay between epigenetic modifiers and oncogenic pathways, potentially uncovering vulnerabilities that can be targeted with epigenetic therapeutics.
These polyclonal knockout cells are suitable for ChIP-qPCR to assess H3K9me3 occupancy, immunofluorescence for HP1?? localization, and Western blotting for CBX5 and interacting factors. They support cell viability and colony formation assays to evaluate tumorigenicity, as well as RNA-seq for transcriptome profiling. They are also useful for screening epigenetic drugs. For detailed product specifications, validation data inquiries, or technical support, please contact Ascent Research.
